Stevanato Group S.p.A. (STVN) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

21/25

Growth 4 Margin 5 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

21
Stevanato Group (STVN) Q2 2026: High-Value Solutions Reach 45% of Revenue, Powering Margin Expansion
August 04, 2026
22
Stevanato Group (STVN) Q1 2026: GLP-1 Revenue Jumps to 22%, Cartridge Capacity Fully Booked
May 07, 2026
22
Stevanato Group (STVN) Q4 2025: High-Value Solutions Rise to 49% of Revenue, Anchoring Margin Expansion
March 04, 2026
22
Stevanato Group (STVN) Q3 2025: High-Value Solutions Jump to 49% of Revenue, Accelerating Strategic Mix Shift
November 06, 2025
22
Stevanato (STVN) Q2 2025: High-Value Solutions Hit 42% Mix, Margin Expansion Signals Biologics Tailwind
August 05, 2025
20
Stevanato (STVN) Q2 2025: High-Value Solutions Hit 42% of Revenue, Margin Expansion Signals Strategic Mix Shift
August 05, 2025
22
Stevanato (STVN) Q1 2025: High-Value Solutions Jump 25%, Accelerating Margin Expansion and U.S. Localization
July 07, 2025
19
Stevanato Group (STVN) Q4 2024: High-Value Solutions Drive 15% Revenue Mix Expansion Amid Vial Demand Recovery
March 06, 2025

Browse all companies